Akt2 - AKT serine/threonine kinase 2 Gene

Rattus norvegicus

Gene ID: 25233 | Gene type: protein coding

About Akt2

Primary_assembly 1: 82,883,547-82,933,817 forward strand.mRatBN7.2:CM026974.1

This gene has 4 transcripts (splice variants), 237 orthologues, 5 paralogues and is associated with 31 phenotypes. Biased expression in Muscle (RPKM 265.6), Heart (RPKM 231.4) and 9 other tissues.

Summary

Enables ATP binding activity; protein kinase C binding activity; and protein serine/threonine kinase activity. Involved in several processes, including negative regulation of nitrogen compound metabolic process; positive regulation of glucose import; and positive regulation of nitrogen compound metabolic process. Acts upstream of or within cellular response to Insulin stimulus and positive regulation of sodium ion transport. Located in several cellular components, including insulin-responsive compartment; mitochondrion; and sarcoplasmic reticulum. Used to study high grade glioma and ischemia. Biomarker of colorectal cancer; hepatocellular carcinoma; hypertension; and obesity. Human ortholog(s) of this gene implicated in glucose metabolism disease (multiple); hypoinsulinemic hypoglycemia with hemihypertrophy; and reproductive organ Cancer (multiple). Orthologous to human Akt2 (Akt serine/threonine kinase 2). [provided by Alliance of Genome Resources, Apr 2022]

Akt2 Products(1)

mRNA	Protein	Name
NM_017093.1	NP_058789.1	RAC-beta serine/threonine-protein kinase

Gene Ontology

Molecular Function
Biological Process
Cellular Component

Molecular Function GO Annotation	Evidence	Reference	Source
enables ATP binding	IDA IDA: Inferred from direct assay	9880520	RGD
enables protein binding	IPI IPI: Inferred from physical interaction	15684423	RGD
enables protein kinase C binding	IPI IPI: Inferred from physical interaction	7488143	RGD
enables protein serine/threonine kinase activity	IDA IDA: Inferred from direct assay	9880520	RGD

Biological Process GO Annotation	Evidence	Reference	Source
involved in cellular response to hormone stimulus	IEP IEP: Inferred from expression pattern	15196698	RGD
acts upstream of or within cellular response to insulin stimulus	IMP IMP: Inferred from mutant phenotype	17715136	RGD
involved in cellular response to organic cyclic compound	IDA IDA: Inferred from direct assay	11812651	RGD
involved in negative regulation of RNA splicing	IMP IMP: Inferred from mutant phenotype	19116344	RGD
involved in negative regulation of apoptotic process	IMP IMP: Inferred from mutant phenotype	19084003	RGD
involved in negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	IMP IMP: Inferred from mutant phenotype	18348079	RGD
involved in phosphatidylinositol 3-kinase/protein kinase B signal transduction	IMP IMP: Inferred from mutant phenotype	16469952	RGD
involved in positive regulation of D-glucose import	IMP IMP: Inferred from mutant phenotype	18335029	RGD
involved in positive regulation of cell migration	IMP IMP: Inferred from mutant phenotype	19330838	RGD
involved in positive regulation of gene expression	IMP IMP: Inferred from mutant phenotype	15557754	RGD
involved in positive regulation of nitric oxide biosynthetic process	IMP IMP: Inferred from mutant phenotype	18335029	RGD
involved in positive regulation of peptidyl-serine phosphorylation	IMP IMP: Inferred from mutant phenotype	18348079	RGD
involved in positive regulation of positive chemotaxis	IDA IDA: Inferred from direct assay	19330838	RGD
involved in positive regulation of protein phosphorylation	IMP IMP: Inferred from mutant phenotype	19116344	RGD
involved in positive regulation of signal transduction	IMP IMP: Inferred from mutant phenotype	19084003	RGD
acts upstream of or within positive regulation of sodium ion transport	IMP IMP: Inferred from mutant phenotype	17715136	RGD
involved in positive regulation of transcription by RNA polymerase II	IMP IMP: Inferred from mutant phenotype	16469952	RGD
involved in protein phosphorylation	IDA IDA: Inferred from direct assay	9880520	RGD
involved in response to hypoxia	IEP IEP: Inferred from expression pattern	29676955	RGD
involved in response to insulin	IDA IDA: Inferred from direct assay	15684423	RGD
involved in response to insulin	IEP IEP: Inferred from expression pattern	18335029	RGD
involved in response to muscle activity	IEP IEP: Inferred from expression pattern	11809761	RGD
involved in response to nutrient levels	IEP IEP: Inferred from expression pattern	18094069	RGD

Cellular Component GO Annotation	Evidence	Reference	Source
located in insulin-responsive compartment	IDA IDA: Inferred from direct assay	9516411	RGD
located in sarcoplasmic reticulum	IDA IDA: Inferred from direct assay	29676955	RGD
located in vesicle	IDA IDA: Inferred from direct assay	9880520	RGD

EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Akt2 Protein Structure

PH_PKB

STKc_PKB_beta

0
100
200
300
400
496 a.a.

Protein Preferred Names

Protein Names

RAC-beta serine/threonine-protein kinase

AKT2 kinase	PKB beta
RAC protein kinase beta RAC-PK beta	RAC-PK-beta
murine thymoma viral (v-akt) oncogene homolog 2	protein kinase Akt-2
protein kinase B beta	thymoma viral proto-oncogene 2
v-akt murine thymoma viral oncogene homolog 2

Related Agents

Clinical Phase

Bioactive Molecules (20)

Cat. No.	Product Name	Effect	Purity	Phase
HY-15186	Ipatasertib	Inhibitor	99.88%	Phase 4
HY-N0004	Oridonin	Inhibitor	99.89%	Phase 4
HY-15431	Capivasertib	Inhibitor	99.95%	Phase 3
HY-15186A	Ipatasertib dihydrochloride	Inhibitor	99.27%	Phase 3
HY-10358	MK-2206 dihydrochloride	Inhibitor	99.99%	Phase 2
HY-19719	Miransertib	Inhibitor	99.32%	Phase 2
HY-15727	Afuresertib	Inhibitor	99.53%	Phase 2
HY-15965	Uprosertib	Inhibitor	99.74%	Phase 2
HY-19934A	Pifusertib hydrochloride	Inhibitor	96.71%	Phase 2
HY-15727A	Afuresertib hydrochloride	Inhibitor	99.95%	Phase 2
HY-19719A	Miransertib hydrochloride	Inhibitor	99.74%	Phase 2
HY-108232	MK-2206	Inhibitor	/	Phase 2
HY-19934	Pifusertib	Inhibitor	/	Phase 2
HY-10357	MK-2206 free base	Inhibitor	/	Phase 2
HY-15965A	Uprosertib hydrochloride	Inhibitor	/	Phase 2
HY-10249	GSK-690693	Inhibitor	99.03%	Phase 1
HY-100018	BAY1125976	Inhibitor	99.52%	Phase 1
HY-16071	AT13148	Inhibitor	99.21%	Phase 1
HY-137458	Vevorisertib	Inhibitor	/	Phase 1
HY-15186C	Ipatasertib tosylate	Inhibitor	/	Phase 1

Pre-clinical Phase

Bioactive Molecules (24)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-10355	AKT inhibitor VIII	Inhibitor	98.97%	Unkown
HY-10425	A-443654	Inhibitor	99.71%	Unkown
HY-12059	AT7867	Inhibitor	99.88%	Unkown
HY-133120	INY-03-041	Inhibitor	99.74%	Unkown
HY-137458A	Vevorisertib trihydrochloride	Inhibitor	99.13%	Unkown
HY-151504	ALM301	Inhibitor	99.65%	Unkown
HY-13260	CCT128930	Inhibitor	99.69%	Unkown
HY-145282	MS170	Inhibitor	99.72%	Unkown
HY-12059A	AT7867 dihydrochloride	Inhibitor	99.75%	Unkown
HY-16666	3CAI	Inhibitor	98.32%	Unkown
HY-50862	Akt1/Akt2-IN-1	Inhibitor	99.30%	Unkown
HY-19982	AKT-IN-6	Inhibitor	99.08%	Unkown
HY-133120A	INY-03-041 trihydrochloride	Inhibitor	99.27%	Unkown
HY-126257	AKT-IN-3	Inhibitor	99.29%	Unkown
HY-13260A	CCT128930 hydrochloride	Inhibitor	98.97%	Unkown
HY-151613	MS15	Inhibitor	/	Unkown
HY-132302	Hu7691	Inhibitor	/	Unkown
HY-129119	Akt1/Akt2-IN-2	Inhibitor	98.57%	Unkown
HY-145281	MS98	Inhibitor	/	Unkown
HY-132302A	Hu7691 free base	Inhibitor	/	Unkown
HY-138767	AKT-IN-5	Inhibitor	/	Unkown
HY-147937	AKT-IN-13	Inhibitor	/	Unkown
HY-143611	AKT-IN-8	Inhibitor	/	Unkown
HY-16032	Akt1-IN-2	Inhibitor	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Akt2	NCBI	NCBI:208
Mus musculus	Akt2	NCBI	NCBI:11652

Name
Email *

	Sorry, but the email address you supplied was invalid.